New triple attack tested against tough liver cancer
NCT ID NCT05166239
Summary
This study tested if adding a direct liver chemotherapy infusion to a standard two-drug regimen (lenvatinib and a PD-1 inhibitor) works better for advanced liver cancer that has spread into a major vein. It involved 66 participants with this specific condition. The goal was to see if the three-part combination was safe and more effective at controlling the cancer and helping patients live longer without the disease getting worse.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking Univerisity Cancer Hospital
Beijing, Beijing Municipality, 100142, China
Conditions
Explore the condition pages connected to this study.